Myasthenia gravis in patients with thymoma affects survival rate following extended thymectomy

Zhang,Zhefeng; Cui,Youbin; Jia,Rui; Xue,Lei; Liang,Huagang

doi:10.3892/ol.2016.4528

Myasthenia gravis in patients with thymoma affects survival rate following extended thymectomy

Authors:
- Zhefeng Zhang
- Youbin Cui
- Rui Jia
- Lei Xue
- Huagang Liang
View Affiliations

Affiliations: Department of Thoracic Surgery, The First Hospital of Qinhuangdao, Qinhuangdao, Hebei 066000, P.R. China, Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: May 5, 2016 https://doi.org/10.3892/ol.2016.4528
Pages: 4177-4182

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thymomas are the most common adult tumors in the anterior mediastinal compartment, and a significant amount of thymomas are complicated by myasthenia gravis (MG). Extended thymectomy (ET) is the primary treatment method for thymomas and is used to completely resect possible ectopic thymus to avoid recurrence. Studies on the effect of MG in thymoma patients following ET are limited. The aim of the present study was to determine whether the presence of MG affects the prognosis of patients with thymoma. The present study consisted of 104 patients with thymoma that underwent ET; 61 men (58.7%) and 43 women (41.3%) (mean age, 54.6 years). In total, 38 patients had MG (36.5%). MG was most frequently observed in World Health Organization (WHO) classification type B2 thymoma compared with other types of thymoma. During the 5‑year follow‑up period, 11 patients succumbed to a recurrence of thymoma or respiratory failure due to MG. The overall 5‑year survival rate in patients without MG or with MG was 89.1 and 76.0%, respectively. The overall survival (OS) rate in patients with Masaoka stages I + II and III + IV was 90.0 and 68.0%, respectively. The OS rate in patients with WHO type A + AB + B1 and type B2 + B3 was 96.9 and 76.8%, respectively. The patients with MG (P=0.026), Masaoka stages III + IV (P=0.008) and WHO type B2 + B3 (P=0.032) had a poorer prognosis compared with patients without these characteristics. Furthermore, multivariate analysis by Cox regression revealed that age [P=0.032; relative risk (RR)=1.097; 95% confidence interval (CI)=1.097‑1.192] and MG (P=0.042; RR=0.167; 95% CI=0.037‑0.940) significantly affected OS rate. In summary, ET is a reliable method for the treatment of thymoma. Long‑term survival is expected for patients at early Masaoka stages, and for patients without MG. The prognosis of patients with thymomas with MG is poorer compared with patients without MG. The present findings provide useful information for the future management of patients with thymomas.

View Figures

View References

1	Ruffini E and Venuta F: Management of thymic tumors: A European perspective. J Thorac Dis. 6(Suppl 2): S228–S237. 2014.PubMed/NCBI
2	Engels EA: Epidemiology of thymoma and associated malignancies. J Thorac Oncol. 5(10 Suppl 4): S260–S265. 2010. View Article : Google Scholar : PubMed/NCBI
3	Baas P and Rhodius R: Thymoma update 2011. Eur J Cancer. 47(Suppl 3): S315–S316. 2011. View Article : Google Scholar : PubMed/NCBI
4	Koppitz H, Rockstroh JK, Schüller H, Standop J, Skowasch D, Müller-Hermelink HK and Schmidt-Wolf IG: State-of-the-art classification and multimodality treatment of malignant thymoma. Cancer Treat Rev. 38:540–548. 2012. View Article : Google Scholar : PubMed/NCBI
5	Detterbeck FC and Parsons AM: Management of stage I and II thymoma. Thorac Surg Clin. 21:59–67, vi–vii. 2011. View Article : Google Scholar : PubMed/NCBI
6	Kaiser LR: Surgical treatment of thymic epithelial neoplasms. Hematol Oncol Clin North Am. 22:475–488. 2008. View Article : Google Scholar : PubMed/NCBI
7	Suster S and Moran CA: Thymoma classification: Current status and future trends. Am J Clin Pathol. 125:542–554. 2006. View Article : Google Scholar : PubMed/NCBI
8	Thomas CR, Wright CD and Loehrer PJ: Thymoma: State of the art. J Clin Oncol. 17:2280–2289. 1999.PubMed/NCBI
9	Fujii Y: Thymus, thymoma and myasthenia gravis. Surg Today. 43:461–466. 2013. View Article : Google Scholar : PubMed/NCBI
10	Regnard JF, Magdeleinat P, Dromer C, Dulmet E, de Montpreville V, Levi JF and Levasseur P: Prognostic factors and long-term results after thymoma resection: A series of 307 patients. J Thorac Cardiovasc Surg. 112:376–384. 1996. View Article : Google Scholar : PubMed/NCBI
11	Masaoka A: Staging system of thymoma. J Thorac Oncol. 5(10 Suppl 4): S304–S312. 2010. View Article : Google Scholar : PubMed/NCBI
12	Ströbel P, Marx A, Zettl A and Müller-Hermelink HK: Thymoma and thymic carcinoma: An update of the WHO Classification 2004. Surg Today. 35:805–811. 2005. View Article : Google Scholar : PubMed/NCBI
13	Bushan K, Sharma S and Verma H: A review of thymic tumors. Indian J Surg Oncol. 4:112–116. 2013. View Article : Google Scholar : PubMed/NCBI
14	Kelly RJ: Thymoma versus thymic carcinoma: Differences in biology impacting treatment. J Natl Compr Canc Netw. 11:577–583. 2013.PubMed/NCBI
15	Lamarca A, Moreno V and Feliu J: Thymoma and thymic carcinoma in the target therapies era. Cancer Treat Rev. 39:413–420. 2013. View Article : Google Scholar : PubMed/NCBI
16	Ruffini E, Detterbeck F, Van Raemdonck D, Rocco G, Thomas P, Weder W, Brunelli A, Evangelista A and Venuta F: European Association of Thoracic Surgeons (ESTS) Thymic Working Group: Tumours of the thymus: A cohort study of prognostic factors from the European Society of Thoracic Surgeons database. Eur J Cardiothorac Surg. 46:361–368. 2014. View Article : Google Scholar : PubMed/NCBI
17	Lucchi M and Mussi A: Surgical treatment of recurrent thymomas. J Thorac Oncol. 5(10 Suppl 4): S348–S351. 2010. View Article : Google Scholar : PubMed/NCBI
18	Riely GJ and Huang J: Induction therapy for locally advanced thymoma. J Thorac Oncol. 5(10 Suppl 4): S323–S326. 2010. View Article : Google Scholar : PubMed/NCBI
19	Gadalla SM, Rajan A, Pfeiffer R, Kristinsson SY, Björkholm M, Landgren O and Giaccone G: A population-based assessment of mortality and morbidity patterns among patients with thymoma. Int J Cancer. 128:2688–2694. 2011. View Article : Google Scholar : PubMed/NCBI
20	Nakagawa K, Asamura H, Matsuno Y, Suzuki K, Kondo H, Maeshima A, Miyaoka E and Tsuchiya R: Thymoma: A clinicopathologic study based on the new World Health Organization classification. J Thorac Cardiovasc Surg. 126:1134–1140. 2003. View Article : Google Scholar : PubMed/NCBI
21	Patel S, Macdonald OK, Nagda S, Bittner N and Suntharalingam M: Evaluation of the role of radiation therapy in the management of malignant thymoma. Int J Radiat Oncol Biol Phys. 82:1797–1801. 2012. View Article : Google Scholar : PubMed/NCBI
22	Rena O, Papalia E, Oliaro A, Ruffini E, Filosso P, Novero D, Maggi G and Casadio C: Does adjuvant radiation therapy improve disease-free survival in completely resected Masaoka stage II thymoma? Eur J Cardiothorac Surg. 31:109–113. 2007. View Article : Google Scholar : PubMed/NCBI
23	Detterbeck FC: Evaluation and treatment of stage I and II thymoma. J Thorac Oncol. 5(10 Suppl 4): S318–S322. 2010. View Article : Google Scholar : PubMed/NCBI
24	Kondo K and Monden Y: Thymoma and myasthenia gravis: A clinical study of 1,089 patients from Japan. Ann Thorac Surg. 79:219–224. 2005. View Article : Google Scholar : PubMed/NCBI
25	López-Cano M, Ponseti-Bosch JM, Espin-Basany E, Sánchez-Garcia JL and Armengol-Carrasco M: Clinical and pathologic predictors of outcome in thymoma-associated myasthenia gravis. Ann Thorac Surg. 76:1643–1649, disc 1649. 2003. View Article : Google Scholar : PubMed/NCBI
26	Margaritora S, Cesario A, Cusumano G, Meacci E, D'Angelillo R, Bonassi S, Carnassale G, Porziella V, Tessitore A, Vita ML, et al: Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. Ann Thorac Surg. 89:245–252; discussion 252. 2010. View Article : Google Scholar : PubMed/NCBI
27	Kondo K, Yoshizawa K, Tsuyuguchi M, Kimura S, Sumitomo M, Morita J, Miyoshi T, Sakiyama S, Mukai K and Monden Y: WHO histologic classification is a prognostic indicator in thymoma. Ann Thorac Surg. 77:1183–1188. 2004. View Article : Google Scholar : PubMed/NCBI
28	Okumura M, Ohta M, Tateyama H, Nakagawa K, Matsumura A, Maeda H, Tada H, Eimoto T, Matsuda H and Masaoka A: The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: A clinical study of 273 patients. Cancer. 94:624–632. 2002. View Article : Google Scholar : PubMed/NCBI
29	Yu S, Li F, Chen B, Lin J, Yang M, Fu X, Li J and Bu B: Eight-year follow-up of patients with myasthenia gravis after thymectomy. Acta Neurol Scand. 131:94–101. 2015. View Article : Google Scholar : PubMed/NCBI
30	Sun XG, Wang YL, Liu YH, Zhang N, Yin XL and Zhang WJ: Myasthenia gravis appearing after thymectomy. J Clin Neurosci. 18:57–60. 2011. View Article : Google Scholar : PubMed/NCBI
31	Yu L, Zhang XJ, Ma S, Jing Y, Li F and Krasna MJ: Different characteristics of thymomas with and without myasthenia gravis. Ann Surg Oncol. 19:94–98. 2012. View Article : Google Scholar : PubMed/NCBI